pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,922 catalysts · 4,876 phase readout · 2,367 8k filing · 286 earnings · 275 pdufa · 138 phase 2 completion · 64 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,876
  • 8k filing2,367
  • earnings286
  • pdufa275
  • phase 2 completion138
  • phase 1 completion64
  • phase 1 initiation39
  • phase 2 initiation35
  • phase 1 2 completion29
  • phase 0 trial completion22
  • therapy area
    • Oncology122
    • Infectious Disease36
    • Cardiology33
    • Immunology25
    • Dermatology21
    • Pulmonology16
    • Ophthalmology12
    • Women's Health11
    • Pain10

    Week of Apr 27, 2026

    50
    ›Apr 29, 2026phase 1 initiation89d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 1 initiation89d agoAgios Pharmaceuticals Inc — AG-181 (Phase I Trial Initiation)AG-181

    Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)

    full page →AG-181 →source: globaldata
    ›Apr 29, 2026phase 1 initiation89d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoTexas Christian University — Alii Supplement (Phase II Trial Completion)Alii Supplement

    Therapy area: Nutritional Disorders. Indication: Unspecified Nutritional Disorders

    full page →Alii Supplement →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoNational Institute of Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Women's Health. Indication: Menorrhagia

    full page →unani medicine →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoGovernment Medical College and Hospital Chandigarh — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 29, 2026phase 2 results89d agoSt. Vincent Health System — [177Lu]Lu-PSMA-597 (Phase II Trial Results)[177Lu]Lu-PSMA-597

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer

    full page →[177Lu]Lu-PSMA-597 →source: globaldata
    ›Apr 29, 2026phase 2 3 completion89d agoFaculty of Medicine Chulalongkorn University — melatonin ER (Phase II/III Trial Completion)melatonin ER

    Therapy area: Gastrointestinal. Indication: Irritable Bowel Syndrome

    full page →melatonin ER →source: globaldata
    ›Apr 29, 2026phase 2 3 initiation89d agoPacific Dental College and Hospital — nicotine (Phase II/III Trial Initiation)nicotine

    Therapy area: Central Nervous System. Indication: Addictive Disorders, Smoking Cessation

    full page →nicotine →source: globaldata
    ›Apr 29, 2026phase 3 completion89d agoBuddhachinaraj Hospital — nefopam (Phase III Trial Completion)nefopam

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Osteoarthritis, Post-Operative Pain

    full page →nefopam →source: globaldata
    ›Apr 29, 2026phase 3 completion89d agoAstraZeneca Plc — durvalumab (Phase III Trial Completion)durvalumab

    Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer

    full page →durvalumab →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoChia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)TQH-2722

    Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis

    full page →TQH-2722 →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoAll India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)Jelmyto

    Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma

    full page →Jelmyto →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoAceLink Therapeutics Inc — AL-1211 (Phase III Trial Initiation)AL-1211

    Therapy area: Metabolic Disorders. Indication: Fabry Disease

    full page →AL-1211 →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoGan & Lee Pharmaceuticals Co Ltd — (insulin aspart + insulin aspart protamine) (Phase III Trial Initiation)(insulin aspart + insulin aspart protamine)

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →(insulin aspart + insulin aspart protamine) →source: globaldata
    ›Apr 29, 2026phase iii iv trial initiation89d agoChettinad Hospital and Research Institute — undisclosed local anesthesia (Phase III/IV Trial Initiation)undisclosed local anesthesia

    Therapy area: Central Nervous System. Indication: Pain

    full page →undisclosed local anesthesia →source: globaldata
    ›Apr 29, 2026phase iv trial initiation89d agoNucleic Acids to the Rescue GmbH — undisclosed chemotherapy (Phase IV Trial Initiation)undisclosed chemotherapy

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 29, 20268k filing89d ago$BIIB — BIOGEN INC. (BIIB) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$IONS — IONIS PHARMACEUTICALS INC (IONS) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d agoTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$AGIO — AGIOS PHARMACEUTICALS, INC. (AGIO) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$REGN — REGENERON PHARMACEUTICALS, INC. (REGN) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$AMRN — AMARIN CORP PLC\UK (AMRN) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$TNXP — Tonix Pharmaceuticals Holding Corp. (TNXP) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$ABBV — AbbVie Inc. (ABBV) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$ANIK — Anika Therapeutics, Inc. (ANIK) — 8-K filing

    Items: 2.02, 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$NVNO — enVVeno Medical Corp (NVNO) — 8-K filing

    Items: 2.02, 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$SGMO — SANGAMO THERAPEUTICS, INC (SGMO) — 8-K filing

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$KALV — KalVista Pharmaceuticals, Inc. (KALV) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$GKOS — GLAUKOS Corp (GKOS) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$FEMY — FEMASYS INC (FEMY) — 8-K filing

    Items: 5.07

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$PODD — INSULET CORP (PODD) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$VRTX — VERTEX PHARMACEUTICALS INC / MA (VRTX) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$MDXG — MIMEDX GROUP, INC. (MDXG) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$MPLT — MapLight Therapeutics, Inc. (MPLT) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ← prev
    page 5 of 159
    next →
    $OCGN1.2100-4.72%
    $INCY117.67+0.84%
    $AZN169.26+0.59%
    $AGIO36.36+0.22%